Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems

Ghassan Tashkandi, Alexey Goltsov, Peter Mullen, James Bown, David Harrison, Simon Langdon

Research output: Contribution to journalMeeting Abstract

Original languageEnglish
Pages (from-to)B33
Number of pages1
JournalMolecular Cancer Therapeutics
Volume14
Issue number7, Suppl.
DOIs
Publication statusPublished - Jul 2015
EventAmerican Association for Cancer Research Special Conference: Targeting he PI3K-mTOR Network in Cancer - Philadelphia, United States
Duration: 14 Sep 201417 Sep 2014

Cite this

Tashkandi, Ghassan ; Goltsov, Alexey ; Mullen, Peter ; Bown, James ; Harrison, David ; Langdon, Simon. / Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems. In: Molecular Cancer Therapeutics. 2015 ; Vol. 14, No. 7, Suppl. pp. B33.
@article{d13feb66bd484dd0b08b3030d8fd1032,
title = "Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems",
author = "Ghassan Tashkandi and Alexey Goltsov and Peter Mullen and James Bown and David Harrison and Simon Langdon",
year = "2015",
month = "7",
doi = "10.1158/1538-8514.PI3K14-B33",
language = "English",
volume = "14",
pages = "B33",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7, Suppl.",

}

Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems. / Tashkandi, Ghassan; Goltsov, Alexey; Mullen, Peter; Bown, James; Harrison, David; Langdon, Simon.

In: Molecular Cancer Therapeutics, Vol. 14, No. 7, Suppl., 07.2015, p. B33.

Research output: Contribution to journalMeeting Abstract

TY - JOUR

T1 - Understanding resistance mechanisms to PI3K/mTOR inhibitors in ovarian cancer model systems

AU - Tashkandi, Ghassan

AU - Goltsov, Alexey

AU - Mullen, Peter

AU - Bown, James

AU - Harrison, David

AU - Langdon, Simon

PY - 2015/7

Y1 - 2015/7

U2 - 10.1158/1538-8514.PI3K14-B33

DO - 10.1158/1538-8514.PI3K14-B33

M3 - Meeting Abstract

VL - 14

SP - B33

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7, Suppl.

ER -